2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
249
Breast Neoplasms
136
Neoplasms
108
Prostatic Neoplasms
35
Fatigue
35
Obesity
25
Lung Neoplasms
24
Colorectal Neoplasms
24
Polycystic Ovary Syndrome
17
Colonic Neoplasms
16
Ovarian Neoplasms
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Pancreatic Neoplasms
11
Lymphoma
11
Lymphedema
11
Hematologic Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Weight Loss
10
Rectal Neoplasms
10
Multiple Myeloma
10
Head and Neck Neoplasms
10
Leukemia
9
Insulin Resistance
8
Cardiotoxicity
8
Brain Neoplasms
8
Stomach Neoplasms
7
Peripheral Nervous System Diseases
7
Overweight
6
Esophageal Neoplasms
6
Cognitive Dysfunction
6
Interventions
Nivolumab
2
sotrovimab
1
gusacitinib
1
ciclesonide
1
cabozantinib
1
anifrolumab
1
Standard of Care
1
Specimen Handling
1
Procalcitonin
1
Practice Guidelines as Topic
1
Platinum Compounds
1
Niclosamide
1
Methods
1
Ipilimumab
1
Interviews as Topic
1
Immune Checkpoint Inhibitors
1
High-Intensity Interval Training
1
Exercise
1
Educational Status
1
Early Intervention, Educational
1
Cholecalciferol
1
CTLA-4 Antigen
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lupus Erythematosus, Systemic
×
Exercise
×
Clear all
NCT05478018
2025-09-09
LUPEX
Rigshospitalet, Denmark
Phase NA
Completed
55 enrolled